Simulations Plus (NASDAQ:SLP) Releases FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $1.07-$1.20 for the period, compared to the consensus EPS estimate of $1.01. The company issued revenue guidance of $90-$93 million, compared to the consensus revenue estimate of $90.71 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SLP. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday. Stephens initiated coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. BTIG Research cut their price target on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. Finally, KeyCorp reduced their price objective on shares of Simulations Plus from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $49.00.

Simulations Plus Trading Down 7.2 %

NASDAQ:SLP opened at $28.21 on Thursday. The firm’s fifty day simple moving average is $29.79 and its 200 day simple moving average is $34.00. Simulations Plus has a twelve month low of $24.00 and a twelve month high of $51.22. The firm has a market capitalization of $566.60 million, a price-to-earnings ratio of 57.57 and a beta of 0.80.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.18 earnings per share. On average, analysts predict that Simulations Plus will post 1.1 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now directly owns 3,442,584 shares in the company, valued at approximately $109,336,467.84. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 19.40% of the stock is currently owned by company insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.